In addition, a study employing primitive CD34+CD38− leukemia initiating cells (LICs) from CML patients showed that OM can effectively kill BCR–ABL+ LICs in vitro [55]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.